Incyte (INCY) Down 0.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/02/21
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell LymphomaBusiness Wire • 08/26/21
Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater ChinaBusiness Wire • 08/16/21
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/03/21
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 08/03/21
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilationPRNewsWire • 08/03/21
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygenPRNewsWire • 07/29/21
Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)Business Wire • 07/23/21
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitisPRNewsWire • 07/16/21
Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD PatientsBenzinga • 07/15/21
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host DiseaseBusiness Wire • 07/14/21